TL;DR: The most revealing development in Silicon Valley's longevity movement is not a new compound or breakthrough protocol, but a retreat. That shift comes as some of the movement's most prominent figures begin confronting the limits of a science that has yet to live up to the hype.
Bryan Johnson, the tech entrepreneur who turned his body into a public experiment, stopped taking Rapamycin in September 2024 after several years of self-testing the drug. The immunosuppressant, which is clinically used to prevent organ rejection, had been a cornerstone of his longevity regimen since 2019. Over the years, he experimented with different doses and schedules to determine whether it could slow the aging process.
Over time, Johnson reported intermittent skin infections, elevated glucose levels, abnormal lipid readings, and an increased resting heart rate. "With no other underlying causes identified, we suspected Rapamycin, and since dosage adjustments had no effect, we decided to discontinue it entirely," he wrote on X.
Johnson first gained widespread attention after selling his payments company, Braintree, to PayPal. He later devoted much of his wealth and attention to Blueprint, a highly structured longevity program built around diagnostics, pharmaceuticals, peptides, and strict lifestyle interventions.
He and his team say they want to move beyond simply managing chronic conditions and instead, as they put it, "tackle chronic conditions that current medicine accepts as manageable but not treatable, and to render them treatable through advanced diagnostics and next-generation personalized therapeutics."
His regimen is constantly refined and publicly documented in remarkable detail, transforming what would once have been a private medical record into something resembling an open-source software project.
Surrounding Johnson is a broader tech community that views longevity as an engineering challenge. Founders, investors, and engineers study early-stage research, engage directly with scientists, and then apply elements of that research to themselves. They track biomarkers through custom testing panels, monitor sleep and physical activity, and share charts detailing mTOR inhibitor use, lipid levels, and biological age estimates.
The feedback loop plays out across X, podcasts, YouTube channels, and private group chats, where data, lab results, and personal protocols are exchanged at a pace more commonly associated with software development.
– Bryan Johnson (@bryan_johnson) November 19, 2024
This culture has helped popularize a succession of compounds and interventions long before large-scale human trials or regulators have had a chance to catch up. Exogenous ketone supplements, for example, gained a following in Silicon Valley as a way to raise blood ketone levels, lower glucose, and sharpen focus. They were marketed as premium cognitive enhancers for executives and engineers.
Then, in March, entrepreneur Tim Ferriss and venture capitalist Kevin Rose used their podcast to warn listeners about 1,3-butanediol, a compound found in some of those products. Ferriss pointed to animal data suggesting it could induce a condition resembling fatty liver disease in mice and told listeners, "Treat it like ethanol, like you're drinking moonshine. You wouldn't want to do that every day."
The animal findings have not been confirmed in humans, and some manufacturers dispute that characterization. However, the message to their audience was clear: proceed with caution.
Rapamycin itself illustrates how scientific research and tech culture interact. In animal models, the drug has been shown to extend lifespan by roughly 25% to more than 50% by inhibiting the mTOR pathway, which regulates cell growth and is implicated in aging.
Scientists such as biogerontologist Matt Kaeberlein note that "it works in every animal where it's ever been tested." Small human studies of a related compound, everolimus, have also shown improved influenza vaccine responses and fewer respiratory infections in older adults, suggesting potential benefits for immune function.
Survey research involving people taking Rapamycin off-label has found that users often report a better quality of life. However, the data is self-reported and may exclude people who discontinued the drug because of side effects.
Even scientists who are optimistic about longevity research stress that these findings do not amount to proof that any current intervention can extend human lifespan. "There is no medical intervention that is proven to extend human life by targeting aging itself," Andrew Steele, an independent longevity researcher and author, told Nature.
Nir Barzilai, president of the Academy of Geroscience and a genetics researcher at Albert Einstein College of Medicine, describes many of the compounds used by wealthy biohackers as biologically plausible but not yet supported by clinical evidence. "If you're asking, 'Is he taking something that doesn't make sense?' I would say no. These things are based on biology, but not on clinical evidence," he says of Johnson's regimen.
The gap between early biological signals and rigorous clinical data is what concerns researchers most. Kaeberlein calls it a "signal-to-noise problem": intriguing findings are scattered across animal studies, small clinical trials, and mechanistic research, but they are often buried beneath a much larger volume of anecdotes, marketing claims, and fast-moving online discussion.
For non-experts, separating credible evidence from speculation can be difficult, especially when information is presented alongside technical jargon, biomarker charts, and laboratory screenshots.
Clinicians working at the forefront of preventive and longevity medicine say the tech community's influence is increasingly making its way into exam rooms. At Reborne Longevity, a London clinic founded by entrepreneur Faye Mythen, clients increasingly arrive asking specifically for drugs, compounds, or Blueprint-style protocols they have encountered online.
"People ask for 'the Blueprint,' or for a specific molecule by name, before they have had a single biomarker measured," Mythen says. She describes this as a "shadow phase II" problem. Affluent self-experimenters conduct their own uncontrolled trials and, through social media, those protocols can quickly spread to a much broader audience without the safeguards built into formal clinical trial phases.
Researchers who study influencers see a similar pattern. Margje Camps of Utrecht University notes that prominent figures in the longevity space often rely heavily on scientific terminology and data visualizations to justify their choices, making their content persuasive even when definitive evidence is lacking.
Followers, she says, can come away with the impression that supplements or drugs are necessary because "everyone is using them, surely I need one," without realizing that some influencers also sell products under their own brand names, creating financial incentives that are not always apparent.
Within the field, there is broad agreement that a handful of existing approved drugs – such as metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and bisphosphonates – have shown promise in slowing or modifying age-related diseases. Barzilai is leading a major study called TAME, which aims to determine whether metformin can delay the onset or progression of chronic conditions associated with aging. Even so, these efforts move slowly compared with the pace of self-experimentation on social media platforms.
Johnson and his Blueprint science team argue that the tech model – dense, individualized measurement through "n-of-1" experiments – represents a new frontier capable of generating "signals that lie beyond the published literature and constitute first-in-human observations."
Barzilai and other geroscientists counter that "science is not n = 1" and that randomized controlled trials remain the gold standard for determining what works at scale. Steele estimates that a properly powered rapamycin trial in healthy adults could cost tens of millions of dollars – a manageable sum given the fortunes of some longevity advocates. Yet he says he has not found a way to channel the "multibillion-dollar excitement" surrounding longevity into that kind of shared scientific infrastructure.
"It's simultaneously a wellness fad and potentially the greatest revolution in the history of medicine," he says.
For now, the clearest sign of how the tech community is reshaping longevity science may be its own public reversals. A founder abandons a drug after years of advocacy. A popular podcast warns listeners to treat a once-hyped compound like moonshine. These moments highlight both the influence and the limitations of treating aging as just another system to be optimized – and how much formal science still has to do to catch up.
Silicon Valley's longevity drug obsession is facing its first real reality check
